47.16 0.00 (0.00%)
After hours: 4:02PM EDT
|Bid||46.50 x 100|
|Ask||49.45 x 200|
|Day's Range||46.92 - 47.38|
|52 Week Range||38.05 - 58.37|
|PE Ratio (TTM)||18.58|
|Forward Dividend & Yield||1.28 (2.61%)|
|1y Target Est||60.40|
In 4Q17, Novo Nordisk’s (NVO) Saxendra generated revenues of 697 million Danish kroner, which reflected a ~38% YoY (year-over-year) growth in local currency.
In 4Q17, Novo Nordisk’s (NVO) hemophilia drugs NovoSeven and NovoEight generated revenues of 2.4 billion Danish kroner and 274 billion Danish kroner, respectively. That’s a ~3% and 1% YoY (year-over-year) growth in local currency.
ROSELAND, N.J., April 26, 2018-- Emisphere Technologies, Inc. today announced that it has amended its existing 2015 Development and License Agreement with Novo Nordisk A/S for the development and commercialization ...
In 4Q17, Novo Nordisk’s (NVO) Victoza generated revenues of 6.3 billion Danish kroner, which reflected a ~25% YoY (year-over-year) growth in local currency.
In 1Q18, analysts expect Sanofi’s (SNY) revenue to fall ~6.6% YoY (year-over-year) to 8.1 billion euros from 8.7 billion euros, and its earnings per share to fall to 1.13 euros from 1.42 euros. Sanofi’s stock price has fallen ~9.4% over the last 12 months and ~7.1% year-to-date. Analysts’ price target of $47.67 suggests the stock could return ~19.2% over the next 12 months based on its price of $39.95 on April 23.
Novo Nordisk’s (NVO) modern insulins include NovoRapid, Levemir, and NovoMix. In 4Q17, its modern insulins generated revenues of 10.4 billion Danish kroner, which is a ~9% YoY (year-over-year) decline in local currency.
In 4Q17, Novo Nordisk’s (NVO) Tresiba generated revenues of 1.9 billion Danish kroner, which is a ~48% YoY (year-over-year) growth in local currency.
In December 2017, the FDA approved Novo Nordisk’s (NVO) Ozempic as an add-on to diet and exercise for the management of blood sugar levels in adult individuals with Type 2 diabetes.
Eli Lilly & Co. (LLY) surpassed Wall Street analysts’ estimates for earnings per share (or EPS) and revenues during 4Q17. The company reported EPS of $1.14 on revenues of ~$6.2 billion, compared to the estimated EPS of $1.07 on revenues of ~$5.9 billion. Analysts expect the company to report EPS of $1.14 on revenues of $5.5 billion during 1Q18.
Novartis AG (NVS) reported revenue of $12.9 billion and EPS (earnings per share) of $1.21 in 4Q17, a 4.8% rise in revenue compared to 4Q16. For 1Q18, analysts expect Novartis to see EPS of $1.28 on revenue of $12.6 billion.
Alcon, Novartis’s (NVS) eye care business, includes surgical products and vision care products. Alcon products are marketed in over 180 countries worldwide. Alcon is expected to report growth in revenue following increased demand for contact lenses and surgical products in 1Q18.
Novartis’s (NVS) Innovative Medicines segment includes cardio-metabolic products, oncology products, immunology and dermatology products, respiratory products, neuroscience products, and established products.
Novo Nordisk announces the availability of Zonovate® for the treatment of patients with hemophilia A in Quebec
Novo Nordisk launches Rebinyn®, a new, long-acting treatment for patients with hemophilia B in Canada
Novo Nordisk (NVO) is a global pharmaceutical company dealing with discovery, development, manufacturing, and commercialization of pharmaceutical products. The company has segregated its business into two segments: Diabetes & Obesity Care and Biopharmaceuticals.
Novo Nordisk (NVO) secures a global licence for United States' biotech company EpiDestiny's sickle cell disease program EPI01.
Danish drugmaker Novo Nordisk has secured the global licence for U.S. biotech company EpiDestiny's sickle cell disease (SCD) programme in a bid to offset declining sales in its biopharmaceutical business. Novo, best known for its diabetes drugs, is on the hunt for promising assets to boost its struggling blood products business after it lost out to French rival Sanofi in the chase for Belgian biotech company Ablynx in January. "This is a great opportunity for Novo Nordisk to enter into a new therapeutic area closely related to our existing biopharmaceutical business," said chief scientific officer Mads Krogsgaard Thomsen.
Bagsværd, Denmark, 3 April 2018 - In continuation of the company`s announcements dated 1 November 2017 and 5 February 2018 concerning planned share repurchase programmes, and pursuant to Section 204.25 ...
NEW YORK, March 28, 2018-- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of ...
A dozen drugs launching in 2018 from heavy-hitters like Roche, Gilead and J&J are expected to hit blockbuster status over the next five years, an analytics firm predicted Thursday.
The 30 most obese countries in the world in 2018 represent a huge (pun intended) market opportunity for weight loss drugmakers. Increasingly sedentary lifestyles and a lack of healthy eating habits among large swaths of the global population have resulted in dramatically rising obesity rates in the past few decades, particularly in urban settings. Obesity is […]
Leading diabetes drugmaker Novo Nordisk (NOVOb.CO) has named former oil boss Helge Lund as its new chairman as the company contends with increasing price pressure and seeks acquisitions to broaden its blood products line-up. The man dubbed by some as Norway's Mr Oil because of his extensive career in the oil and gas industry may be more of an expert in hydrocarbons than insulin, but his merger and acquisitions experience is a big draw for the Danish pharmaceuticals company.